Vertex Pharmaceuticals (VRTX) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Vertex Pharmaceuticals (VRTX)

VRTX 426.82

+1.1%

Nov 21 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: David Lieberman who started this subject	9/24/2001 11:15:01 AM
From: IRWIN JAMES FRANKEL	Read Replies (1) of 1169

9:50AM Vertex Pharm (VRTX) 17.68 -5.79: Sources at SG Cowen telling Briefing.com that discontinuing development of VX745 will be viewed negatively. VX745 was in Phase II testing for rheumatoid arthristis (RA). It was discontinued due to adverse affects. Company will continue to test VX740 with partner Aventis, also for RA-could enter Phase III in 2002. However, firm believes discontinuation will hurt stock and co will be viewed as a tech platform story, rather than a drug stock.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next